TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02989402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Description: 15 cm\^2 patch sizes loaded with 27 mg of rivastigmine - one patch per day
Study: NCT00045799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole sodium bicarbonate immediate release PWD/FS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cimetidine IV
Study: NCT03714464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole apples
Description: 350 of whole apples containing 49g of available carbohydrate with 173ml water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apple puree
Description: 384g of apple puree containing 44g of available carbohydrates with 224 ml water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apple Juice
Description: 338g apple juice containing 46g of available carbohydrate with 260 ml water
Study: NCT02039778

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stem Cell Radiotherapy (ScRT) and Temozolomide
Description: Stem Cell Radiotherapy (ScRT) and Temozolomide:~The postoperative surgical bed + edema + margin \& the ipsilateral subventricular zone (contoured as a 5mm rim of tissue around the ipsilateral lateral ventricles) will be included within the initial target volume and treated to 46 Gy in 23 fractions. After 46 Gy, the conedown or boost volume (surgical cavity + margin) will be treated to a total of 60 Gy, with seven additional fractions of 2 Gy each (14Gy boost dose).~Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2. The drug will be administered orally on an empty stomach, the first dose to be given the night prior or morning of the first radiation fraction, and continued until the last radiation fraction is completed (including weekends and holidays).
Study: NCT01275144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: Administered orally
Study: NCT00152113

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hematopoietic Stem Cell Transplantation
Description: Allogeneic stem cell transplant Haploidentical stem cell transplant Mismatched family member donor stem cell transplant T cell selection CD34 enrichment

Intervention type: DEVICE
Group type: OTHER
Intervention: CliniMACS

Intervention type: DRUG
Group type: OTHER
Intervention: See intervention description
Description: Hydroxyurea and azathioprine were administered for a 3 month period prior to the initiation of the transplant procedure in an effort to help prevent rejection of the donor product. Approximately 10 days prior to the transplant procedure, all participants received the same preparative regimen consisting of Busulfan, cyclophosphamide, low-dose thiotepa, and OKT3. MMF was administered for GVHD prophylaxis. Two separate infusions of donor stem cells were administered with fixed doses of CD3 and CD34 cells. These haploidentical stem cells were processed using the investigational CliniMACS device.
Study: NCT02952690

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glidescope® with tip manipulated stylet
Description: The intubating style is curved in accordance with the curve of GVL blade and the distal tip of style is additionally bended to the left (15-20 degree)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope® with standard-curved tip
Description: The style is curved in accordance with the curve of GVL blade
Study: NCT04009187

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-person wheelchair propulsion training program
Description: The wheelchair propulsion (WP) intervention is based on our previous pilot work and the best available evidence on WP training. The CPGs recommend minimizing the force and frequency of pushes while using long strokes during propulsion. Each training session will include massed practice with repetitions overground. Each session is organized to limit the number of variables (i.e., long push strokes and dropping the hands down below axle) presented to the participant at one time. Propulsion Set A will focus on using longer push strokes. Propulsion Set B will focus on dropping the hand down toward the axle. Propulsion Set C will focus on both A and B.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 30-minute education session
Description: Both groups will receive a 30-minute education session regarding the CPGs. This education session will follow the instructions provided in Rice and colleagues. (L. A. Rice et al., 2014). It consists of the importance of practicing biomechanical efficient propulsion. The material lists out the consequences and the impact of upper limb pain and injury. It provides a detailed step by step on how to propel properly. They will view the video that shows the biomechanics of efficient and inefficient propulsion.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 30-minute education session
Description: Both groups will receive a 30-minute education session regarding the CPGs. This education session will follow the instructions provided in Rice and colleagues. (L. A. Rice et al., 2014). It consists of the importance of practicing biomechanical efficient propulsion. The material lists out the consequences and the impact of upper limb pain and injury. It provides a detailed step by step on how to propel properly. They will view the video that shows the biomechanics of efficient and inefficient propulsion.
Study: NCT00918593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Electrochemotherapy
Description: Intratumoral or intravenous bleomycin followed by electric pulses. Once only treatment.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Radiotherapy according to hospital procedures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: Intratumoral or intravenous bleomycin followed by electric pulses. Once only treatment.
Study: NCT00970021

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Intake of 60 ml placebo daily in addition to chemotherapy
Description: The patients will drink 60 ml of placebo daily from start of stem cell mobilizing treatment until one week after the end of aplasia after high dose melphalan. Duration of treatment is approximately 7 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Intake of 60 ml agaricus daily in addition to chemotherapy
Description: The patients will drink 60 ml of agaricus extract from the start of stem cell mobilizing treatment until one week after the end of aplasia after high dose melphalan. Duration of treatment: Approximately 7 weeks
Study: NCT00397605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synthetic cannabinoids (1:1 ratio of THC % CBD)
Description: Randomized crossover study of 2 weeks of active study medication (maximum daily dosage of 60 mg) vs. 2 weeks of matching placebo.
Study: NCT04312243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide gas
Description: Control group: a SARS-CoV2 rt-PCR will be performed if symptoms arise. Treatment group: the subjects will breathe NO at the beginning of the shift and before leaving the hospital. Inspired NO will be delivered at 160 parts per million (ppm) for 15 minutes in each cycle. A SARS-CoV-2 rt-PCR will be performed if symptoms arise. Safety: Oxygenation and methemoglobin levels will be monitored via a non-invasive CO-oximeter. If methemoglobin levels rise above 5% at any point of the gas delivery, inhaled NO will be halvened. NO2 gas will be monitored and maintained below 5 ppm.
Study: NCT05501392

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: STEPS-PreK
Description: Intervention group received the BN CHSP, a Texas Education Agency (TEA)-approved CSHP. This health program was first piloted in schools located in low-income neighborhoods where enrollment was predominantly Black and Latino children. The Social-Ecological Model guided the BN CSHP design. This theory postulates that health behaviors are molded by individual, interpersonal, and environmental interactions. Thus, BN CSHP encompasses curricula from preschool to eighth grade and is designed to target the four environments that influence children's health behaviors: 1) Healthy Lifestyles Healthy Minds (Health), 2) Moving For Life (Physical Education), 3) Eat to Live (Child Nutrition/School Food Service), and 4) MyFamily/MiFamilia (Home).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEPS-PreK
Description: Intervention group received the BN CHSP, a Texas Education Agency (TEA)-approved CSHP. This health program was first piloted in schools located in low-income neighborhoods where enrollment was predominantly Black and Latino children. The Social-Ecological Model guided the BN CSHP design. This theory postulates that health behaviors are molded by individual, interpersonal, and environmental interactions. Thus, BN CSHP encompasses curricula from preschool to eighth grade and is designed to target the four environments that influence children's health behaviors: 1) Healthy Lifestyles Healthy Minds (Health), 2) Moving For Life (Physical Education), 3) Eat to Live (Child Nutrition/School Food Service), and 4) MyFamily/MiFamilia (Home).
Study: NCT00477802

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Injected once during the course of the study.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injected once during the course of the study.
Study: NCT03779347

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Praziquantel
Description: Praziquantel to treat schistosomiasis during pregnancy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Praziquantel
Description: Praziquantel to treat schistosomiasis during pregnancy

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: UCP-LF CAA
Description: UCP-LF CAA to diagnose Schistosomiasis during pregnancy

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: composite diagnostic
Description: composite diagnostic reference test based on extensive egg microscopy, serology, qPCR on egg DNA, and POC-CCA to diagnose Schistosomiasis during pregnancy
Study: NCT03513679

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical intervention
Description: Surgery to decompress the spinal cord, either with or without concurrent fusion
Study: NCT01211756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 20 IU BID for one week, followed by 40 IU BID for 3 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 IU BID for one week, followed by 40 IU BID for 3 weeks.
Study: NCT02686164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 24 mg (as one 4 mg and two 10 mg capsules) will be administered orally once daily with 240 mL (8 fluid oz) of water each morning, starting on Cycle 1 Day 1, in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam syrup 4 mg will be administered orally after an overnight fast on Cycle 1 Day -3 and concurrently with lenvatinib on Day 1 and Day 14 of Cycle 1. Participants will have to remain fasting for 2 hours after each dose of midazolam.
Study: NCT01091246

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Q/LAIV (MEDI3250)
Description: 10 \^7.0 ± 0.5 FFU/dose of each of 4 influenza virus strains: A/H1N1, A/H3N2, B/Yamagata, and B/Victoria

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluMist/B/Yamagata
Description: 10 \^7.0 ± 0.5 FFU/dose of each of 3 influenza virus strains: A/H1N1, A/H3N2, and B/Yamagata

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluMist/B/Victoria
Description: 10 \^7.0 ± 0.5 FFU/dose of each of 3 influenza virus strains: A/H1N1, A/H3N2, and B/Victoria
Study: NCT04226781

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hyperspectral-Imaging
Description: Photos were taken with the hyperspectral camera of the gastrointestinal anastomosis.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Indocyaningreen-Fluorescence imaging
Description: Photos were taken with the Fluorescence camera after injection of the indocyaningreen-dye of the gastrointestinal anastomosis
Study: NCT03002636

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anesthesia
Description: Anesthesia : (1) General Anesthesia (GA)(2) Epidural Anesthesia (EA) (3) Combined Spinal-Epidural Anesthesia (CSEA)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: anesthesia
Description: Anesthesia : (1) General Anesthesia (GA)(2) Epidural Anesthesia (EA) (3) Combined Spinal-Epidural Anesthesia (CSEA)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anesthesia
Description: Anesthesia : (1) General Anesthesia (GA)(2) Epidural Anesthesia (EA) (3) Combined Spinal-Epidural Anesthesia (CSEA)
Study: NCT03421938

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking Exercise
Description: Group 1 will have downhill walking exercises with %10 slope; group 2 uphill walking exercises on the treadmill with %10 slope..

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking Exercise
Description: Group 1 will have downhill walking exercises with %10 slope; group 2 uphill walking exercises on the treadmill with %10 slope..
Study: NCT05148637

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance of general anesthesia by Sevoflurane
Description: Anesthesia was maintained by inhalational anesthesia (sevoflurane) titrated by monitoring of patient sensitivity index of the Masimo
Study: NCT00981136

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single Incision Laparoscopic Appendectomy
Description: A single incision through the umbilicus to remove the appendix

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3 port laparoscopic appendectomy
Description: Standard 3 port laparoscopic appendectomy with intracorporeal stapling
Study: NCT02649504

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab will be given at the standard dose of 375mg/m2 on days 1, 8, 15, 22 of the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Rituximab will be given at the standard dose of 375mg/m2 on days 1, 8, 15, 22 of the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone will be given at dose 40 mg/day on days 1-4, 15-18, and 29-32 (+/- 3 days) of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone will be given at dose 40 mg/day on days 1-4, 15-18, and 29-32 (+/- 3 days) of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Patients allocated to the active drug arm will be given Mycophenolate mofetil starting on day 33, 500 mg twice daily for the first week and then escalation to 1000 mg twice daily for 24 weeks.
Study: NCT05148637

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance of general anesthesia by Desflurane
Description: Anesthesia was maintained by inhalational anesthesia (desflurane) titrated by monitoring of patient sensitivity index of the Masimo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anesthesia was maintained by inhalational anesthesia (total intravenous anesthesia by lidocaine, propfol and fentanyl infusions)
Description: Anesthesia was maintained by inhalational anesthesia (total intravenous anesthesia by lidocaine, propfol and fentanyl infusions) titrated by monitoring of patient sensitivity index of the Masimo
Study: NCT02649504

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients allocated to the placebo arm will be given placebo starting on day 33, 500 mg twice daily for the first week and then escalation to 1000 mg twice daily for 24 weeks.
Study: NCT04343976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon lambda
Description: 180 mcg subcutaneous injection of pegylated interferon lambda

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegylated interferon lambda
Description: 180 mcg subcutaneous injection of pegylated interferon lambda
Study: NCT00911768

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng Powder Capsule
Description: Generic name: Korean Red Ginseng Powder Capsule Original herb name: Panax ginseng Form and contents: Capsule with powder of steamed root of 6-year Panax ginseng Dosage and frequency: 6 g per day (twice a day), Oral administration Administration duration: 56 days in the study

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn-starch powder with ginseng flavor
Description: There is no specific name because this intervention is placebo. This placebo has the same form, color and flavor as Korean Red Ginseng Powder Capsule.~The dosage form, dosage, frequency and duration is also same as experimental intervention (Korean Red Ginseng Powder Capsule).~Main contents: corn-starch with Panax ginseng flavor
Study: NCT01909297

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PROSEAL LMA
Description: Size 3,4 or 5 supraglottic device with orogastric drainage tube

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SUPREMA LMA
Description: Size 3,4 or 5, disposable supraglottic device with orogastric drainage tube

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I-GEL LMA
Description: Size 3,4,5 disposable supraglottic device with noninflatable cuff
Study: NCT04265326

Intervention type: OTHER
Intervention: Measurement of Quality of Life
Description: Quality of life will be measured using Head and Neck Cancer Inventory and The Functional Assessment of Cancer Therapy - Head and Neck Cancer Version 4
Study: NCT04158804

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: procalcitonin
Description: accuracy of procalcitonin as a diagnostic marker in guiding antibiotic therapy in patients with a lower respiratory tract infection
Study: NCT03759782

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Ribavirin will be added to the standard of care treatment (tenofovir) regime for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Tenofovir as per standard of care
Study: NCT03621033

Intervention type: PROCEDURE
Group type: OTHER
Intervention: colonic transendoscopic enteral tubing
Description: The procedure colonic transendoscopic enteral tubing is as follows:The TET tube was inserted into the ileocecal junction through the endoscopy channel at the first time of the cecal intubation after examination and evaluation of the whole colon. Then, the colonoscope was removed from the colon while the TET tube was maintained at the ileocecal junction. Then the endoscopy was inserted into the ileocecum again for affixing the TET tube to cecum with titanium clips.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: colonic transendoscopic enteral tubing
Description: The procedure colonic transendoscopic enteral tubing is as follows:The TET tube was inserted into the ileocecal junction through the endoscopy channel at the first time of the cecal intubation after examination and evaluation of the whole colon. Then, the colonoscope was removed from the colon while the TET tube was maintained at the ileocecal junction. Then the endoscopy was inserted into the ileocecum again for affixing the TET tube to cecum with titanium clips.
Study: NCT02874313

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure
Description: Nocturnal continuous positive airway pressure by a nasal mask. CPAP pressure will be automatically titrated using a AutoSet device (ResMed).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment
Description: Conventional pharmacological treatment with oral antidiabetic drugs or insulin
Study: NCT03759782

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Description: Tenofovir as per standard of care
Study: NCT00613899

Intervention type: OTHER
Group type: OTHER
Intervention: telesurveillance
Description: A telesurveillance program for cough assistance will be approched by the use of an in-exoflator device. Measurement of oxygen saturation (SpO2) will be performed by a Nonin 9500 oxymeter (Minneapolis Plymouth USA).
Study: NCT00930670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin-omeprazole
Description: Rosuvastatin 20 mg for 1 month. Then rosuvastatin 20mg and omeprazole 20mg for 11 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin-pantoprazole
Description: Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and pantoprazole 40 mg for 11 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin-esomeprazole
Description: Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and esomeprazole 40 mg for 11 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin-ranitidine
Description: Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and ranitidine 300mg for 11 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin-omeprazole
Description: Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and omeprazole 20 mg for 11 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin-pantoprazole
Description: Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and pantoprazole 40 mg for 11 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin-esomeprazole
Description: Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and esomeprazole 40 mg for 11 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin-ranitidine
Description: Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and ranitidine 300mg for 11 months
Study: NCT01883102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin 0.1%
Description: Cream will be cleansed from sites A and B with soap and water each morning before reapplying.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cream will be cleansed from sites A and B with soap and water each morning before reapplying.
Study: NCT03655743

Intervention type: DEVICE
Intervention: LASIK, PRK, Phacoemulsification
Description: Please see:~https://en.wikipedia.org/wiki/LASIK https://en.wikipedia.org/wiki/Photorefractive_keratectomy https://en.wikipedia.org/wiki/Phacoemulsification

Intervention type: DEVICE
Intervention: LASIK, PRK, Phacoemulsification
Description: Please see:~https://en.wikipedia.org/wiki/LASIK https://en.wikipedia.org/wiki/Photorefractive_keratectomy https://en.wikipedia.org/wiki/Phacoemulsification